By: TPS Staff
The British pharmaceutical company AstraZeneca and U.S.-based Daiichi Sankyo developed a new lung cancer treatment called Datroway (datopotamab deruxtecan). It has received accelerated approval from the FDA for use in adults with non-small cell lung cancer who have already received chemotherapy treatment.
The approval is based on early trial results showing promising effectiveness, but continued approval will require further clinical data. Datroway’s approval offers a new option for patients that have developed resistance to earlier treatments and who have exhausted other effective therapies.
